1. New Horizons in the Management of Advanced Breast Cancer

2. Program Overview

3. Recent Therapeutic Advances in HR-Positive, HER2-Negative Breast Cancer

4. High Rate of ESR1 Mutations Identified in cfDNA Analysis of Plasma Samples From BOLERO-2

5. Prophylactic Mouth Rinse for Everolimus-Related Stomatitis

6. Subgroup Analysis of Stomatitis in the BALLET Study

7. The PI3K Pathway in Breast Cancer

8. Phase 3 BELLE-2: Buparlisib + Fulvestrant in Advanced HR-Positive Disease

9. Adjuvant ET ± Everolimus: Phase 3 Trials

10. PALLAS: Adjuvant ET ± Palbociclib in HR-Positive, HER-Negative EBC

11. Immunotherapy in HR-Positive Breast Cancer

12. Conclusions

13. Abbreviations

14. Abbreviations (cont)